Nevro Corp. (NYSE: NVRO) Investor Securities Class Action Lawsuit 08/23/2018

If you purchased a significant amount of shares of Nevro Corp. (NYSE: NVRO) between January 8, 2018 and July 12, 2018, and / or if you purchased any NYSE: NVRO shares prior to January 2018 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: October 22, 2018. NYSE: NVRO investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to, or call us at (858) 779-1554.
Company Name(s): 
Case Name: 
Nevro Shareholder Class Action Lawsuit 08/23/2018
Case Status: 
Lawsuit Filed
Affected Securities
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
Class Period Begin: 
Class Period End: 
Court of Filing: 
U.S. District Court for the Northern District of California
Deadline To File for Lead: 

An investor in shares of Nevro Corp. (NYSE: NVRO) filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by Nevro Corp. in connection with certain allegedly false and misleading statements made between January 8, 2018 and July 12, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of Nevro Corp. (NYSE: NVRO) common shares between January 8, 2018 and July 12, 2018, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between January 8, 2018 and July 12, 2018, the defendants allegedly made false and/or misleading statements and/or failed to disclose that that Nevro had engaged in a fraudulent scheme by using protected confidential and proprietary trade secrets and stolen documents from its competitors to develop and enhance the Company's Senza systems, that as a result, the Company's Senza systems were not "novel" or "proprietary;", that these practices caused the Company to be vulnerable to increased litigation expenses and adverse legal and regulatory action, that, as a result, Nevro's U.S. sales growth was not sustainable, and that, as a result of the foregoing, Defendants' statements about Nevro's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Redwood City, CA based Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally.

On January 8, 2018 Nevro Corp. announced its preliminary unqudited fourth quarter and fiscal year 2017 revenue.

On Februayr 8, 2018, Nevro Corp announced its fourth quarter and full year 2017 financial results and provided its 2018 outlook. reported that its annuala Total Revenue rose from $228.5 million in 2016 rose to $326.67 million in 2017 and that its Net Loss increased from $31.77 million in 2016 to $36.65 million in 2017.

On July 13, 2018, Nevro Corp. announced its preliminary second quarter worldwide revenue. On July 16, 2018, Nevro Corp. announced its preliminary unaudited second quarter 2018 revenue and updated its full year 2018 revenue guidance.

Shares of Nevro Corp. (NYSE: NVRO) declined in end of July 2018 to as low as $35.41 per share.